🇺🇸 FDA
Pipeline program

Placebo

ALN-TTR02-011

Phase 3 small_molecule completed

Quick answer

Placebo for Transthyretin Amyloidosis (ATTR) With Cardiomyopathy is a Phase 3 program (small_molecule) at ALNYLAM PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
ALNYLAM PHARMACEUTICALS, INC.
Indication
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials